Press Release
NeurogesX Appoints Stephen Ghiglieri as Chief Financial Officer
New CFO Brings Experience in IPOs, Acquisitions and LicensingSan Carlos, Calif. - October 20, 2003
NeurogesX today announced it has appointed Stephen F. Ghiglieri as Chief Financial Officer. Mr. Ghiglieri, who has experience in public offerings, acquisitions and licensing for life sciences and software companies, will assume responsibility for all financial aspects of NeurogesX.
"Stephen’s track record in helping emerging growth companies from the R&D phase through product introductions makes him an excellent match for NeurogesX," said Anthony A. DiTonno, CEO and President of NeurogesX. "As we continue making progress in our clinical trials, Stephen’s effective management of our financial resources will play a greater role in our success."
NeurogesX is conducting two sets of pivotal trials, including the treatment of postherpetic neuralgia and the treatment of painful HIV-associated neuropathy.
Mr. Ghiglieri was most recently Chief Financial Officer of Hansen Medical, Inc., Palo Alto, CA, an early stage medical device company. Earlier, he was CFO of Oacis Healthcare Systems, Inc., San Rafael, CA, where he managed the company’s initial public offering and subsequent acquisition by SAIC. Mr. Ghiglieri has also served as CFO of Andromedia, Inc. and Avolent, Inc., both San Francisco software companies, where he managed IPO, M&A and venture financing transactions, including the sale of Andromedia to Macromedia, Inc. He also held financial management positions with Oclassen Pharmaceuticals, Inc. and PricewaterhouseCoopers.
Mr. Ghiglieri received his BA in business administration from California State University at Hayward. He is a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and the Financial Executive Institute.
About NeurogesX
NeurogesX (neur-o-GEE-six) is a privately held specialty pharmaceutical company focusing on the development of products for the treatment of nerve signaling disorders. The company’s initial products are focused on the treatment of chronic and acute pain. The company’s first product, a topical treatment for neuropathic pain, has been evaluated in a Phase II randomized double-blind trial. Two phase II/ III multi-center clinical trials are currently enrolling patients. The company is also conducting Phase II/III trials for the treatment of painful HIV-associated neuropathy. NeurogesX has raised $30 million in total equity investments since its first funding round in June 2000. Investors include Alta Partners, ARCH Venture Partners, Montreux Equity Partners, Grove Street Advisors Affiliated Fund, TIAA (Teachers Insurance and Annuity Association), Duke University, University of North Carolina and Walden International. For more information about NeurogesX, go to www.neurogesx.com.
NeurogesX is a trademark of NeurogesX, Inc. All other trademarks and registered trademarks are those of their respective companies.
Contacts:
Anthony A. DiTonno
CEO and President
NeurogesX, Inc.
aditonno@neurogesx.com
650-508-2116
Stephen F. Ghiglieri
CFO
NeurogesX, Inc.
sghiglieri@neurogesx.com
650-508-2116
Mike Jackman
Jackman Communications
mike@jackman.com
415-388-3216